| |  |  | |  |  | | This is one of the more interesting articles I have read this year: the former dean of Harvard Medical School had a start-up in the late 1980s based on using GLP1s to treat diabetes and weight loss, but Pfizer stopped funding it despite promising early results. Two lessons: | | | | 8/24/24, 6:30 PM |
| |
No comments:
Post a Comment